Table 1_Study on the antibacterial effect of the new anti-biofilm inhibitor ICAC on Escherichia coli.docx by Yubin Bai (1350858)

Image 1_Exploring the effects of aerobic and resistance exercise on mood-related symptoms and EEG activity.tiff by Kihoon Yuk (20950130)

Table 1_Distinct response patterns of endothelial markers to the BNT162b2 mRNA COVID-19 booster vaccine are associated with the spike-specific IgG antibody production.docx by Beatriz Castro-Robles (20506802)

“…</p>Results<p>We identified two significantly distinct profiles of endothelial markers response, characterized by either increased or decreased serum levels of endocan and sVCAM. …”

Rinderine suppresses African swine fever virus replication in porcine alveolar macrophages by dual targeting of membrane-associated profilin 1 and phosphatidylethanolamine by Di Liu (30843)

“…Structural prediction analysis, co-immunoprecipitation assay, and confocal microscopy demonstrate that RIN disrupts the interaction between PFN1 and actin, thereby decreasing the actin remodelling. …”

Table 1_The impact of prebiotics, probiotics and synbiotics on the prevention and treatment of atopic dermatitis in children: an umbrella meta-analysis.docx by Lifeng Wang (121568)

Surgical changes through ISIW implantation. by Sayaka Kimura-Uchida (22793666)

“…Pre- and postoperative data are compared by Tukey’s HSD test and asterisks mean statistical significance (p < 0.05). IOP decreases significantly from 3 to 12 months after surgery whereas GMS decreases from one day to 12 months after surgery. …”

Data Sheet 1_New evidence for T-cadherin in COVID-19 pathogenesis, endothelial dysfunction, and lung fibrosis.docx by Ekaterina Semina (12152564)

Data Sheet 1_Real-life data on pasireotide in monotherapy or combined in active Cushing’s disease.pdf by Alessandro Mondin (22611146)

“…Cholesterol levels tended to decrease, and a significant weight loss was observed (>5% in 47% of cases). …”

Data Sheet 1_An in vitro evaluation of intravenous lipid emulsion on three common canine toxicants.docx by Emery Jones (19736377)

“…ILE therapy may have other means of significantly decreasing lipophilic drug concentration in cases of toxicosis.…”

Table 1_Meta-analysis of the effects of exercise interventions on dialysis patients with cardiac function disorders.docx by Huizhen Liu (1596664)

“…</p>Conclusion<p>Exercise can significantly enhance LVEF and decrease LVMI in dialysis patients. …”

Table 1_Experimental-numerical investigation on the performance of basalt fiber reinforced asphalt mixture.xlsx by Zizhou Xue (22434397)

“…<p>Asphalt mixture stands as one of the extensively utilized materials within the realm of road engineering. …”

SEP-363856 attenuates CUMS-induced depression-like behaviours and reverses hippocampal neuronal injuries by Mengdie Li (7432913)

“…</p> <p>The antidepressant-like effects of SEP-363856 are linked to increased hippocampal neurotrophic factors, decreased hippocampus neuronal lesions, and activation of the IGF-1Rβ/PI3K/AKT signalling pathway. …”

Numbers of nuclei and centrioles per cell. by Yang-In Yim (324355)

“…Note that the values in (D) for HSET KD and combined KD of Myo10 KD and HSET, while significantly different from the control, represent decreases in centriole number, not increases (these decreases may be due to the anti-proliferative effects of HSET KD). …”

Data Sheet 1_The impact of gradient variable temperature fermentation on the quality of cigar tobacco leaves.pdf by Qianying Zhang (2391760)

“…The gradient variable temperature fermentation process underwent a three-phase model to characterize the alterations of CTLs. Phase I (35°C) was the microbial stage, during which there was a significant decrease in both the total number and function of microorganisms. …”

Data Sheet 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and... by Zachary D. Wallen (19986522)

“…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Table 4_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Table 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Table 5_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Table 2_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”

Table 3_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”